AI English summary of an SEC filing — figures as filed

The company said it is beginning the process of finding a successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development, on July 9, 2024.

8-KDeparture or Appointment of Directors or Certain OfficersFiled Jul 10, 2024Period of report Jul 9, 2024Summary published (UTC) Oct 26, 2026

Key points

AI summary

The company said it is beginning the process of finding a successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development, on July 9, 2024.
Pfizer said it has started an external search for a new Chief Scientific Officer.
The company said Dr. Dolsten will continue in his current role until a successor is in place and any necessary transition is complete.
Pfizer said Dr. Dolsten has been with the company for more than 15 years and is expected to remain with Pfizer through at least February 28, 2025.

Summary

AI-written

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Search for successor to chief scientific officer begins

The company said it is beginning the process of finding a successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development, on July 9, 2024.

Source · Based on the filing body and exhibits

External search for new leader launched

Pfizer said it has started an external search for a new Chief Scientific Officer.

Source · Based on the filing body and exhibits

Current role kept until successor is named

The company said Dr. Dolsten will continue in his current role until a successor is in place and any necessary transition is complete.

Source · Based on the filing body and exhibits

Expected to remain through at least February 28, 2025

Pfizer said Dr. Dolsten has been with the company for more than 15 years and is expected to remain with Pfizer through at least February 28, 2025.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.